A Point-of-Care Test for Drug Induced Liver Injury

Abstract

Liver disease poses a significant public health burden, accounting for over 2 million annual, global deaths. A large portion of these cases can be treated (e.g. chronic hepatitis B), cured (e.g. chronic hepatitis C), or prevented (e.g. drug induced liver injury) with prompt diagnosis; therefore, there is a need for tools to aid in prompt diagnosis of liver injury, specifically in low- and middle- income countries. Here, we demonstrate an assay capable of testing for liver biomarkers and adaptable to the point of care.